<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220220054079N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-11-14</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>The Effect of Spirulina Supplementation on Traumatic Brain Injury</public_title>
      <acronym>SSS</acronym>
      <scientific_title>Efficacy of Spirulina Supplementation on Glasgow Outcome ScaleExtended in Patients with Moderate to Severe Traumatic Brain Injury a double-blind, randomized controlled clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>130</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/93659</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Following enrollment, participants are assigned to either the intervention or control group at a 1:1 ratio using block randomization. The randomization sequence is generated and maintained by a second study coordinator—who has no role in patient assessment, data collection, or statistical analysis—using the Randomizer.org website. To ensure allocation concealment, group assignment codes (A and B) are placed in opaque, sealed, and sequentially numbered envelopes; this information is disclosed only to a designated staff member who is not involved in treatment, outcome assessment, or data analysis. This individual is responsible for preparing and administering the intervention to the patient. The Spirulina supplement and the placebo are provided in containers that are identical in shape, size, and appearance, distinguished solely by codes A and B; consequently, patients, healthcare staff, outcome assessors, and the data analyst remain unaware of group assignments, thereby fully maintaining the study's double-blind design. Ultimately, 65 patients will be enrolled in each group, Blinding description: To maintain allocation concealment, following the generation of a randomization sequence using block randomization, group allocation codes (A and B) were placed in opaque, sealed, and numbered envelopes by an independent individual who was not involved in treatment, outcome assessment, or data analysis. The Spirulina supplement and placebo were prepared in identical containers and labeled solely with codes A and B; consequently, patients, healthcare staff, outcome assessors, and the data analyst remained unaware of the group allocations, ensuring the study's double-blind design was fully maintained.</study_design>
      <phase>3</phase>
      <hc_freetext>Brain injury.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: 8 grams of spirulina solution is used once a day for 14 days or until discharge. drug intervention is initiated 24 to 48 hours after admission, and the rout of administration is oral if level of consciousness is adequate, or via NG tube if level of consciousness is not adequate. The raw materials used in this study are provided by the knowledge-based company "Zarkhiz Khak Persia" and the formulation, preparation of the intervention solution and placebo solution are also done by "Saaditab Sina" company. It is worth mentioning that both companies operate under the supervision of the growth center of Shiraz University of Medical Sciences. The intervention solution contains 8 hot cooked spirulina (Spirulina platensis) substances, which are prepared from dried and standardized microalgae, and microbial quality and standards are used. It is prepared as a homogenized suspension in a solvent. Intervention 2: Control group: placebo solution is prepared as a suspension without substances, but with the same volume, color, and viscosity as spirulina solution. placebo solution is started 24 to 48 hours after admission, just like intervention group, and is used for 14 days or until discharge. placebo solution is administered to the patients orally if level of consciousness is adequate, or via NG tube if level of consciousness is not adequate.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The entire dataset can be shared once the individuals have been de-identified.

When:
Access begins upon the conclusion of the study on December 22, 2027.

To whom:
It will be available solely to researchers affiliated with academic and scientific institutions, subject to identity verification and the submission of a well-founded request deemed valid by the principal investigator.

Conditions:
The data are suitable for conducting a systematic review and meta-analysis.

Where to obtain:
Please email Dr. Amin Niakan, the project's principal investigator, to obtain the data. His email address is aminniakan@yahoo.com.

How to obtain:
The applicant must provide full particulars, state the reason for requiring the information, and commit to using the data solely for academic and scholarly purposes—within the scope disclosed to the principal investigator—and refraining from any commercial use. It is understood that any violation of these terms is subject to legal action through university ethics committees and the judicial system.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hasan Avakh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Rajaee Surgical Emergency Center, Before Niayesh Boulevard, Shahid Chamran Boulevard, Shiraz</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۷۱۹۴۸۱۵۷۱۱</zip>
        <telephone>+98 993 378 9672</telephone>
        <email>doctor.hassan.avakh.۱۹۹۳@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hasan Avakh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Rajaee Surgical Emergency Center, Before Niayesh Boulevard, Shahid Chamran Boulevard, Shiraz</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۷۱۹۴۸۱۵۷۱۱</zip>
        <telephone>+98 993 378 9672</telephone>
        <email>doctor.hassan.avakh.۱۹۹۳@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>age 15-65 years old
GCS on admission less than 13
AIS more than 3 in head and less than 3 in other areas</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>GCS 3-4 with fixed dilated pupils
history of significant brain damage like CVA or craniotomy
history of rheumatologic and autoimmune disorders
pregnancy of breast feeding
cardiac arrest on admission
Plt count less than 100,000 on admission
INR more than 1.4 on admission
drug history of current antiplatelet therapy like ASA, Clopidogrel, ticagrelor</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S06.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Diffuse traumatic brain injury</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: 8 grams of spirulina solution is used once a day for 14 days or until discharge. drug intervention is initiated 24 to 48 hours after admission, and the rout of administration is oral if level of consciousness is adequate, or via NG tube if level of consciousness is not adequate. The raw materials used in this study are provided by the knowledge-based company "Zarkhiz Khak Persia" and the formulation, preparation of the intervention solution and placebo solution are also done by "Saaditab Sina" company. It is worth mentioning that both companies operate under the supervision of the growth center of Shiraz University of Medical Sciences. The intervention solution contains 8 hot cooked spirulina (Spirulina platensis) substances, which are prepared from dried and standardized microalgae, and microbial quality and standards are used. It is prepared as a homogenized suspension in a solvent.</i_keyword>
      <i_keyword>Control group: placebo solution is prepared as a suspension without substances, but with the same volume, color, and viscosity as spirulina solution. placebo solution is started 24 to 48 hours after admission, just like intervention group, and is used for 14 days or until discharge. placebo solution is administered to the patients orally if level of consciousness is adequate, or via NG tube if level of consciousness is not adequate.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Glasgow Outcome Scale Extended. Timepoint: 1, 3, and 6 months after starting Spirulina. Method of measurement: Glascow outcome scale extended calculator.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-09-07</approval_date>
        <contact_name>Ethics Committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>Shiraz Medical School, Imam Hossein Square, Zand Street, Shiraz Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
